SCHEMBL18200705

SCHEMBL18200705

c1ccc(-c2cnc(-c3nc4ccccc4c4c3ccc3ccccc34)c3ccccc23)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
LMNA P02545 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
RECQL P46063 1/20 0.41
KDM4E B2RXH2 4/20 0.40
ALDH1A1 P00352 2/20 0.40
HPGD P15428 2/20 0.40
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
TNF P01375 1/20 0.36
GLA P06280 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
ADORA2A P29274 3/20 0.35
TOP2A P11388 1/20 0.35
GPR3 P46089 1/20 0.34
NUDT1 P36639 1/20 0.34
ADORA1 P30542 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18201218 0.89 MAPT (0.43) MAPTNPC1RAB9ALMNASMN1; SMN2
SCHEMBL18200695 0.89 ADORA2A (0.45) MAPTNPC1RAB9ALMNASMN1; SMN2
SCHEMBL18200903 0.89 ADORA2A (0.41) MAPTNPC1RAB9ALMNASMN1; SMN2
SCHEMBL19227294 0.88 HSD17B1 (0.36) MAPTNPC1RAB9ALMNASMN1; SMN2
SCHEMBL18200718 0.87 TOP2A (0.36) MAPTNPC1RAB9ALMNASMN1; SMN2
SCHEMBL18201219 0.87 KDM4E (0.43) MAPTNPC1RAB9ALMNASMN1; SMN2
SCHEMBL18347071 0.87 MAPT (0.42) MAPTNPC1RAB9ALMNASMN1; SMN2
SCHEMBL18201223 0.85 MAPT (0.42) MAPTNPC1RAB9ALMNASMN1; SMN2
SCHEMBL18201252 0.84 MAPT (0.43) MAPTNPC1RAB9ALMNASMN1; SMN2
SCHEMBL18200581 0.84 MAPT (0.35) MAPTNPC1RAB9ALMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9728731-B2 Heterocyclic compound and organic light emitting device using same HEESUNG MATERIAL LTD. (KR) 2017-08-08 US disclosed
US-9728731-B2 Heterocyclic compound and organic light emitting device using same HEESUNG MATERIAL LTD. (KR) 2017-08-08 US disclosed
US-20160380208-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME HEESUNG MATERIAL LTD. (KR) 2016-12-29 US disclosed
EP-3088392-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME Heesung Material Ltd. (KR) 2016-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160380208-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME NOTUM, DDT, CRY1 MAPT 1937/4885NPC1 3875/4885RAB9A 2864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.